View Main Condition: Leukemia
Thomas Kipps is a Hematologist Oncology specialist and an Oncologist in La Jolla, California. Kipps has been practicing medicine for over 44 years and is rated as an Elite expert by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). He is also highly rated in 16 other conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Transplant. He is licensed to treat patients in California. Kipps is currently accepting new patients.
Nicole Lamanna is an Oncologist and a Hematologist in New York, New York. Lamanna has been practicing medicine for over 26 years and is rated as an Elite expert by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). She is also highly rated in 16 other conditions, according to our data. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Bone Marrow Transplant. She is licensed to treat patients in New York. Lamanna is currently accepting new patients.
Danielle Brander is a Hematologist Oncology expert in Durham, North Carolina. Brander has been practicing medicine for over 16 years and is rated as an Elite expert by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). She is also highly rated in 15 other conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in North Carolina. Brander is currently accepting new patients.
Summary: The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Summary: This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.